In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 376 to 400 of 424

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]	Technology appraisal guidance	16 July 2025
Teprotumumab for treating thyroid eye disease [ID6432]	Technology appraisal guidance	20 August 2025
Third molars (impacted) - prophylactic removal [ID898]	Technology appraisal guidance	TBC
Tirzepatide for managing overweight and obesity [ID6179]	Technology appraisal guidance	19 December 2024
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy [ID4070]	Technology appraisal guidance	TBC
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]	Technology appraisal guidance	TBC
Tobacco: preventing uptake, promoting quitting and treating dependence - Cytisine for smoking cessation	NICE guideline	4 February 2025
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]	Technology appraisal guidance	TBC
Topical Antimicrobial dressings for wound care: Late stage assessment	Health technology evaluation	22 May 2025
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]	Technology appraisal guidance	TBC
Total hip arthroplasty using the superpath approach for osteoarthritis	Interventional procedures guidance	TBC
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]	Technology appraisal guidance	TBC
Transcatheter aortic valve implantation for native aortic valve regurgitation	Interventional procedures guidance	11 June 2025
Transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis: Late stage assessment	Health technology evaluation	8 January 2025
Transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia	Interventional procedures guidance	12 December 2024
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]	Technology appraisal guidance	10 September 2025
Treatments for non-small-cell lung cancer [ID6234]	Technology appraisal guidance	TBC
Triheptanoin for treating long-chain fatty acid oxidation disorders ID3891	Technology appraisal guidance	TBC
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]	Technology appraisal guidance	TBC
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]	Technology appraisal guidance	TBC
Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer [ID4061]	Technology appraisal guidance	TBC
Type 2 diabetes in adults: management (medicines update)	NICE guideline	19 June 2025
Ublituximab for treating relapsing multiple sclerosis [ID6350]	Technology appraisal guidance	TBC
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]	Technology appraisal guidance	TBC
Urinary Tract Infection (recurrent): antimicrobial prescribing	NICE guideline	13 November 2024

Results per page

10
25
50
All